Supernus Pharma (SUPN) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Supernus Announces Fourth Quarter and Full Year 2019 Financial Results
February 25, 2020 4:41 PM ESTFourth quarter and full year 2019 total revenue of $100.4 million and $392.8 million, respectively.
Fourth quarter and full year 2019 net product sales of $97.9 million and $383.4 million, respectively.Fourth quarter and full year 2019 operating earnings of $40.8 million and $148.6 million, respectively.FDA assigned PDUFA target action date of November 8, 2020 for review of SPN-812 New Drug Application.Phase III P302 trial of SPN-810 for the treatment of IA in ADHD patients 6 to 11 years old did not meet primary endpoint.
ROCKVILLE, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:... More
